However, in the case of the patient who developed cholecystitis, CHC levels decreased following treatment with cholecystectomy but remained elevated relative to baseline, perhaps reflecting the underlying primary tumor resistance to NAT (Figure 4). This evidence concerns the gene BRD2 and neoplasm.